Cowen initiated coverage on shares of Orchard Therapeutics (NASDAQ:ORTX) in a report published on Sunday, AnalystRatings.com reports. The firm issued a buy rating and a $27.00 target price on the stock.

ORTX has been the topic of a number of other reports. Barclays initiated coverage on shares of Orchard Therapeutics in a research report on Thursday, September 5th. They set an overweight rating and a $21.00 price target on the stock. Zacks Investment Research lowered shares of Orchard Therapeutics from a hold rating to a sell rating in a research report on Friday, August 16th. Oppenheimer initiated coverage on shares of Orchard Therapeutics in a research report on Thursday, August 29th. They set an outperform rating and a $26.00 price target on the stock. Finally, ValuEngine upgraded shares of Orchard Therapeutics from a hold rating to a buy rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. Orchard Therapeutics has an average rating of Buy and an average price target of $24.63.

ORTX opened at $14.54 on Friday. The firm has a market capitalization of $1.29 billion and a PE ratio of -1.42. Orchard Therapeutics has a twelve month low of $8.65 and a twelve month high of $21.64. The firm’s 50-day moving average price is $14.22 and its 200 day moving average price is $15.99. The company has a current ratio of 7.89, a quick ratio of 7.89 and a debt-to-equity ratio of 0.07.

Orchard Therapeutics (NASDAQ:ORTX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.20). As a group, analysts predict that Orchard Therapeutics will post -1.86 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the business. Exane Derivatives acquired a new position in Orchard Therapeutics in the 2nd quarter valued at about $60,000. Maven Securities LTD acquired a new position in Orchard Therapeutics in the 2nd quarter valued at about $144,000. Athanor Capital LP acquired a new position in Orchard Therapeutics in the 2nd quarter valued at about $200,000. D. E. Shaw & Co. Inc. acquired a new position in Orchard Therapeutics in the 2nd quarter valued at about $236,000. Finally, Stanley Laman Group Ltd. acquired a new position in Orchard Therapeutics in the 2nd quarter valued at about $256,000. Institutional investors own 70.58% of the company’s stock.

Orchard Therapeutics Company Profile

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

Recommended Story: Candlestick

Analyst Recommendations for Orchard Therapeutics (NASDAQ:ORTX)

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.